| Literature DB >> 34770960 |
Alejandro Madrid1, Ana Lizeth Morales1, Valentina Saffirio1, Mauricio A Cuellar2, Enrique Werner3, Bastián Said4, Patricio Godoy5, Nelson Caro6, Mirna Melo7, Iván Montenegro8.
Abstract
In this study, the essential oil (EO) from Laurelia sempervirens was analyzed by GC/MS and safrole (1) was identified as the major metabolite 1, was subjected to direct reactions on the oxygenated groups in the aromatic ring and in the side chain, and eight compounds (4 to 12) were obtained by the process. EO and compounds 4-12 were subjected to biological assays on 24 strains of the genus Saprolegnia, specifically of the species 12 S. parasitica and 12 S. australis. EO showed a significant effect against Saprolegnia strains. Compound 6 presents the highest activity against two resistant strains, with minimum inhibitory concentration (MIC) and minimum oomyceticidal concentration (MOC) values of 25 to 100 and 75 to 125 µg/mL, respectively. The results show that compound 6 exhibited superior activities compared to the commercial controls bronopol and azoxystrobin used to combat these pathogens.Entities:
Keywords: Laurelia sempervirens; nitrocompounds; safrol; saprolegniosis
Mesh:
Substances:
Year: 2021 PMID: 34770960 PMCID: PMC8588113 DOI: 10.3390/molecules26216551
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
EO composition of leaves of L. sempervirens.
| N | RT (min) | Components | % Area a | RI b | RI c | Identification |
|---|---|---|---|---|---|---|
| 1 | 10.22 | α-Pinene | 1.48 | 941 | 941 | RL, MS, Co |
| 2 | 10.24 | Camphene | 0.11 | 956 | 957 | RL, MS |
| 3 | 10.32 | α-Phellandrene | 0.33 | 1010 | 1009 | RL, MS |
| 4 | 10.60 | p-Cymene | 0.12 | 1032 | 1033 | RL, MS |
| 5 | 10.77 | β-Phellandrene | 1.08 | 1038 | 1035 | RL, MS, Co |
| 6 | 10.83 | 3-Carene | 0.42 | 1147 | 1148 | RL, MS |
| 7 | 10.88 | Isosafrole | 11.90 | 1227 | 1229 | RL, MS, Co |
| 8 | 11.04 | Safrole | 65.03 | 1293 | 1295 | RL, MS, Co |
| 9 | 11.13 | Piperonal | 0.37 | 1348 | 1347 | RL, MS, Co |
| 10 | 11.94 | 3-Allyl-6-methoxyphenol | 1.13 | 1360 | 1362 | RL, MS |
| 11 | 12.26 | β-Caryophyllene | 0.74 | 1395 | 1396 | RL, MS |
| 12 | 12.52 | α-Gurjunene | 0.24 | 1397 | 1399 | RL, MS |
| 13 | 15.83 | Humelene | 0.35 | 1441 | 1442 | RL, MS |
| 14 | 15.90 | Germacrene D | 2.33 | 1480 | 1480 | RL, MS |
| 15 | 16.05 | Spathulenol | 11.16 | 1560 | 1562 | RL, MS |
| 16 | 16.10 | α-Cadinol | 1.10 | 1615 | 1615 | RL, MS |
| Total identified | 97.89 |
a Surface area of GC peak; b RI: retention indices relative to C8-C36 n-alkanes on the HP-5 MS capillary column; c RI: retention index from the literature [20]. RL: comparison of the RI with those of the literature [21]; MS: comparison of the mass spectra with those of the NIST 14; Co: co-elution with standard compounds available in our laboratory.
Figure 1Structures of the main compounds present in the EO of L. sempervirens.
Figure 2Structure of safrole derivatives 4–12.
MIC values a of leaf EO, safrole and compounds 4–7 against mycelium at 48 h.
| N Strains | MIC (µg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| EO | 1 | 4 | 5 | 6 | 7 | Bronopol | Azoxystrobin | DMSO | |
| 1 | 50 | 125 | 175 | 3.125 | 3.125 | 3.125 | 50 | 100 | i |
| 2 | 75 | 100 | 150 | 6.25 | 6.25 | 6.25 | 50 | 100 | i |
| 3 | 75 | 125 | 150 | 6.25 | 6.25 | 6.25 | 50 | 100 | i |
| 4 | 75 | 100 | 150 | 12.5 | 3.125 | 12.5 | 50 | 100 | i |
| 5 | 100 | 125 | 175 | 25 | 6.25 | 25 | 50 | 75 | i |
| 6 | 125 | 175 | 175 | 50 | 6.25 | 50 | 75 | 125 | i |
| 7 | 100 | 150 | 175 | 50 | 3.125 | 50 | 50 | 100 | i |
| 8 | 100 | 150 | 200 | 50 | 6.25 | 50 | 75 | 150 | i |
| 9 | 125 | 150 | 150 | 50 | 6.25 | 50 | 50 | 100 | i |
| 10 | 125 | 150 | >200 | 50 | 3.125 | 50 | 100 | 100 | i |
| 11 | 100 | 150 | >200 | 50 | 6.25 | 50 | 100 | 100 | i |
| 12 | 125 | 175 | >200 | 50 | 6.25 | 50 | 100 | 100 | i |
| 13 | 150 | 175 | >200 | 50 | 12.5 | 50 | 100 | 100 | i |
| 14 | 150 | 175 | 200 | 50 | 25 | 50 | 100 | 100 | i |
| 15 | 175 | 200 | >200 | 25 | 25 | 50 | 100 | 100 | i |
| 16 | 125 | 150 | >200 | 25 | 50 | 75 | 50 | 100 | i |
| 17 | 75 | 125 | 175 | 12.5 | 25 | 25 | 75 | 100 | i |
| 18 | 50 | 100 | 150 | 6.25 | 50 | 75 | 100 | 100 | i |
| 19 | 75 | 125 | 150 | 50 | 12.5 | 50 | 125 | 100 | i |
| 20 | 150 | 175 | >200 | 100 | 50 | 100 | 150 | 125 | i |
| 21 | 125 | 150 | >200 | 100 | 50 | 100 | 150 | 100 | i |
| 22 | 125 | 175 | >200 | 125 | 75 | 125 | 150 | 100 | i |
a Each value represents the mean of three experiments, performed in quadruplicate. i: inactive.
MIC values a of compounds 8–12 against mycelium at 48 h.
| N Strains | MIC (µg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| 8 | 9 | 10 | 11 | 12 | Bronopol | Azoxystrobin | DMSO | |
| 1 | 12.5 | 50 | 125 | 150 | 100 | 50 | 100 | i |
| 2 | 12.5 | 50 | 125 | 150 | 100 | 50 | 100 | i |
| 3 | 125 | 75 | 100 | 150 | 100 | 50 | 100 | i |
| 4 | 150 | 75 | 125 | 175 | 100 | 50 | 100 | i |
| 5 | 150 | 100 | 150 | 150 | 125 | 50 | 75 | i |
| 6 | 175 | 75 | 125 | 175 | 125 | 75 | 125 | i |
| 7 | 150 | 50 | 150 | 200 | 150 | 50 | 100 | i |
| 8 | >200 | 100 | 200 | 175 | 150 | 75 | 150 | i |
| 9 | 125 | 50 | 125 | 175 | 150 | 50 | 100 | i |
| 10 | 175 | 75 | 200 | 150 | 175 | 100 | 100 | i |
| 11 | 175 | 175 | 200 | >200 | 200 | 100 | 100 | i |
| 12 | 125 | 150 | 150 | 200 | >200 | 100 | 100 | i |
| 13 | 150 | 150 | 175 | >200 | 150 | 100 | 100 | i |
| 14 | 175 | 175 | 175 | >200 | 125 | 100 | 100 | i |
| 15 | 175 | 75 | 200 | >200 | 200 | 100 | 100 | i |
| 16 | >200 | 50 | >200 | 200 | >200 | 50 | 100 | i |
| 17 | 125 | 50 | 175 | 150 | 175 | 75 | 100 | i |
| 18 | 175 | 50 | 175 | >200 | 200 | 100 | 100 | i |
| 19 | 100 | 50 | 125 | 150 | 150 | 125 | 100 | i |
| 20 | 200 | 50 | 200 | 175 | 175 | 150 | 125 | i |
| 21 | 175 | 175 | 175 | 150 | 125 | 150 | 100 | i |
| 22 | 175 | 175 | 175 | 150 | 125 | 150 | 100 | i |
a Each value represents the mean of three experiments, performed in quadruplicate. i: inactive.
Summary of the anti-oomycete activity of EO, safrole and derivatives against resistant strains of S. parasitica and S. australis.
| Compound | ||||||
|---|---|---|---|---|---|---|
| MIC (µg | MOC (µg | Membrane Damage (%) b | MIC (µg | MOC (µg | Membrane Damage (%) b | |
| EO | 50 | 75 | 86.3 ± 0.4 | 75 | 75 | 84.3 ± 0.9 |
| 1 | 125 | 150 | 75.4 ± 0.6 | 150 | 150 | 72.4 ± 1.1 |
| 4 | 150 | 175 | 6.3 ± 0.4 | 175 | 175 | 5.9 ± 0.4 |
| 5 | 150 | 175 | 80.3 ± 0.2 | 175 | 200 | 50.5 ± 0.6 |
| 6 | 25 | 75 | 96.3 ± 0.3 | 100 | 125 | 90.6 ± 0.9 |
| 7 | 100 | 125 | 77.4 ± 0.7 | 150 | 175 | 60.8 ± 0.4 |
| 8 | 125 | 150 | 33.4 ± 0.6 | 175 | 200 | 27.5 ± 0.7 |
| 9 | 100 | 150 | 55.8 ± 0.4 | 150 | 175 | 40.4 ± 0.8 |
| 10 | 150 | 175 | 17.4 ± 0.1 | 175 | 200 | 12.2 ± 0.4 |
| 11 | 200 | >200 | 0 | >200 | >200 | 0 |
| 12 | 150 | 175 | 25.6 ± 0.4 | >200 | >200 | 21.4 ± 0.3 |
| Bronopol | 50 | 100 | 27.1 ± 0.3 | 100 | 150 | 26.0 ± 0.4 |
| Azoxystrobin | 100 | 125 | Nd | 100 | 150 | Nd |
| SDS | - | - | 100 | - | - | 100 |
| DMSO | i | i | i | i | i | i |
a Each value represents the mean of three experiments. b Each value represents the mean ± SD of three experiments, performed in quadruplicate. Nd: not detected; i: inactive.